Medication Error and Intramuscular Extravasation of Vinblastine: A Case Report and Review of Literature

El-Harti Amine *

National Burn Center and Plastic Surgery Department CHU Ibn Rochd, Faculté de Médecine et Pharmacie de Casablanca Hassan 2 University, Morocco.

Sabur Sara

National Burn Center and Plastic Surgery Department CHU Ibn Rochd, Faculté de Médecine et Pharmacie de Casablanca Hassan 2 University, Morocco.

Benkhaldoun Mohamed

National Burn Center and Plastic Surgery Department CHU Ibn Rochd, Faculté de Médecine et Pharmacie de Casablanca Hassan 2 University, Morocco.

Youssfi Ahlam

National Burn Center and Plastic Surgery Department CHU Ibn Rochd, Faculté de Médecine et Pharmacie de Casablanca Hassan 2 University, Morocco.

Karti Sara

National Burn Center and Plastic Surgery Department CHU Ibn Rochd, Faculté de Médecine et Pharmacie de Casablanca Hassan 2 University, Morocco.

Diouri Mounia

National Burn Center and Plastic Surgery Department CHU Ibn Rochd, Faculté de Médecine et Pharmacie de Casablanca Hassan 2 University, Morocco.

*Author to whom correspondence should be addressed.


Abstract

Extravasation accidents involving vesicant chemotherapy products can lead to severe local tissue damage and long-term functional impairment. Intramuscular (IM) extravasation is particularly concerning due to potential deep tissue damage and limited accessibility for treatment. We present a case report of an IM extravasation accident with vinblastine instead of asparaginase in a 15-year-old patient with acute lymphoblastic leukemia B. The patient did not report immediate symptoms, the MRI scans was not available immediately and the management lack of untoward recommendations. options include monitoring, saline flash out and surgical debridement. We opted for saline flash out due to the amount, the nature of the product and the location and risk of further damage. The patient showed successful recovery without further complications during a six-month follow-up. A review of the literature revealed limited number of cases reports of IM extravasation a 4 case reports in 6 patients not including our case. Treatment decisions depend on factors such as the extravasation location, drug amount, and patient health. Understanding the risk of IM extravasation and selecting appropriate management strategies are crucial for minimizing complications and promoting positive outcomes.

Keywords: Accidental extravasation, vesicant chemotherapy, vinblastine, vincristine, intramuscular


How to Cite

Amine , E.-H., Sara , S., Mohamed, B., Ahlam , Y., Sara , K., & Mounia , D. (2023). Medication Error and Intramuscular Extravasation of Vinblastine: A Case Report and Review of Literature. International Research Journal of Oncology, 6(2), 185–190. Retrieved from https://journalirjo.com/index.php/IRJO/article/view/137

Downloads

Download data is not yet available.

References

Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila FESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines Ann Oncol. 2012;23(Suppl 7):vii167–73.

Choy DS. Effective treatment of inadvertent intramuscular administration of vincristine. JAMA. 1979 Feb 16;241(7): 695.PMID: 762824.

Clark BS, Gallegos E, Bleyer WA. Accidental intramuscular vincristine: lack of untoward effects and recommendations for management. Med Pediatr Oncol. 1997; 28:314–5.

Olcay L, Safak T. Inadvertent intramuscular administration of vincristine: lack of untoward effects without any treatment except administration of hot compresses. Pediatr Hematol Oncol. 2003;20:427–8.

Patiroglu T, Unal E, Ozdemir MA, Karakukucu M, Mutlu FT. Accidental intramuscular overdose administration of vincristine. Drug Chem Toxicol. 2012; 35:232–4.

Sugalski J, Stewart FM, Carlson RW.J Natl Compr Canc Netw. NCCN's Commitment to Medication Safety: The Vincristine Initiative.2016 Aug;14(8):959-60.

Radhakrishnan V, Murali A, Mishra S.Indian J Cancer. Inadvertent intramuscular administration of vincristine in two pediatric patients with uneventful outcomes. 2016 Apr-Jun;53(2):303.

Chotsampancharoen T, Sripornsawan P, Wongchanchailert M. Chemotherapy. Two Fatal Cases of Accidental Intrathecal Vincristine Administration: Learning from Death Events. 2016;61(2):108-10.

Bruhwiler LA, Schwappach DLB. Safe vincristine use in Switzerland: still a long way to go? J Oncol Pharm Pract. Epub ahead of print 13 March 2019.

Gilbar P, Dooley M, Brien J. Inadvertent intrathecal administration of vincristine: are we fulfilling our roles as oncology pharmacists? J Oncol Pharm Pract. 2004; 10: 187–189.

Gilbar PJ. Inadvertent intrathecal administration of vincristine: Time to finally abolish the syringe. J Oncol Pharm Pract. 2020 Mar;26(2):263-266.

Stefanou A, Dooley M. A simple method to eliminate the risk of inadvertent intrathecal vincristine administration. J Clin Oncol. 2003;21:2044–2047.

Millichamp T, Johnston ANB. Interventions to support safe medication administration by emergency department nurses: An integrative review. Int Emerg Nurs. 2020 Mar;49:100811.

Khalil H, Kynoch K, Hines S. Interventions to ensure medication safety in acute care: an umbrella review. Int J Evid Based Healthc. 2020 Jun;18(2):188-211.

Keers RN, Williams SD, Cooke J, Walsh T, Ashcroft DM. Impact of interventions designed to reduce medication administration errors in hospitals: A systematic review. Drug Saf. 2014 May;37(5):317-32.

Rohde E, Domm E. Nurses' clinical reasoning practices that support safe medication administration: An integrative review of the literature. J Clin Nurs. 2018 Feb;27(3-4):e402-e411.

Cabilan CJ, Hughes JA, Shannon C. The use of a contextual, modal and psychological classification of medication errors in the emergency department: a retrospective descriptive study. J Clin Nurs. 2017 Dec;26(23-24):4335-4343.